Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trilogy International Partners Inc T.TRL.WT.A


Primary Symbol: V.TRL.H

Trilogy International Partners Inc. operates through its subsidiary Trilogy International Partners LLC (Trilogy LLC). Prior to the disposal of its New Zealand and Bolivia operations, Trilogy LLC was a provider of wireless voice and data communications services including local, international long distance and roaming services. Trilogy LLC also provided fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia. The Company had two reportable segments identified by their geographic regions, New Zealand and Bolivia. Two Degrees Mobile Limited (2degrees) operated in New Zealand and Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A. (NuevaTel) operated in Bolivia. Both these segments provided a variety of wireless voice and data communications services, including local, international long distance and roaming services. The services were provided to subscribers on both a postpaid and prepaid basis.


TSXV:TRL.H - Post by User

Post by Contrarian333on Jul 24, 2019 5:10pm
167 Views
Post# 29956621

Good News!

Good News!<p> Acerus Pharmaceuticals Corporation (TSX:<span class="foundtext">ASP</span>, OTCQB:ASPCF) (&ldquo;Acerus&rdquo; or the &ldquo;Company&rdquo;) announced today that NATESTO<sup>&reg;</sup> (testosterone nasal gel) is now on formulary and covered nationwide by a leading national pharmacy benefit manager (PBM) in the United States. This PBM contract provides for unrestricted patient access to NATESTO<sup>&reg;</sup> across the PBM&rsquo;s national open formularies and plans that service government clients. Over six million U.S. lives are covered by these prescription plans.</p> <p> &ldquo;The addition of NATESTO<sup>&reg;</sup> to a large national formulary in the United States will enable our partner Aytu Bioscience to accelerate prescription growth for the brand in our most important market. With the signing of this payer contract, over six million new patients have gained access to NATESTO<sup>&reg;</sup>,&rdquo; said Ed Gudaitis, President and Chief Executive Officer of Acerus Pharmaceuticals. &ldquo;We congratulate the team at Aytu for achieving this important milestone.&rdquo;&nbsp;</p>
<< Previous
Bullboard Posts
Next >>